Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|July 27, 2016
ACO Growth Impact on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses the impact of Accountable Care Organizations on specialty pharmacy.
Advertisement
Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses the impact of Accountable Care Organizations on specialty pharmacy.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5